Open AccessJournal Article
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
P. A. J. Janssen,Carlos J. E. Niemegeers,Frans Awouters,K. H. L. Schellekens,Anton Megens,Theo F. Meert +5 more
Reads0
Chats0
TLDR
The first clinical studies indicate that two additional therapeutic targets may be obtained with risperidone in the monotherapy of schizophrenia and related disorders: very important contact and mood-elevating properties and extrapyramidal symptoms-free maintenance therapy.Abstract:
Comparative studies of the benzisoxazole derivative risperidone (R 64 766) were made with ritanserin, a selective centrally acting serotonin-S2 antagonist and with haloperidol, a selective centrally acting dopamine-D2 antagonist. Risperidone like ritanserin shows activity in all tests related to serotonin-S2 antagonism, but at even lower doses (peripheral S2-antagonism at 0.0011 mg/kg, central S2-antagonism at 0.014 mg/kg). Like haloperidol, risperidone shows activity in all tests related to dopamine-D2 antagonism; activity in rats for both compounds starts at 0.016 mg/kg, but some central nervous system controlled functions, including the induction of catalepsy, are relatively much less affected by risperidone. Qualitatively, risperidone is a mixed serotonin-dopamine antagonist. Quantitatively, its study in dogs reveals potent dopamine-D2 antagonistic activity with excellent p.o. bioavailability and a relatively long duration of action. From the obtained pharmacological data, risperidone could be expected to possess the complementary clinical effects of a ritanserin-like serotonin-S2 and an haloperidol-like dopamine-D2 antagonist. Serotonin-S2 antagonism may improve the quality of sleep, reduce negative and affective symptoms in schizophrenic patients and decrease extrapyramidal symptoms induced by classical neuroleptics. Because risperidone is a dopamine-D2 antagonist, antidelusional, antihallucinatory and antimanic actions are expected. The first clinical studies indicate that two additional therapeutic targets, which are not reached with classical neuroleptics, may be obtained with risperidone in the monotherapy of schizophrenia and related disorders: very important contact and mood-elevating properties and extrapyramidal symptoms-free maintenance therapy.read more
Citations
More filters
Journal ArticleDOI
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
A. Schotte,P.F.M. Janssen,W. Gommeren,Walter Luyten,P. Van Gompel,A S Lesage,K. De Loore,J. E. Leysen +7 more
TL;DR: In vitro, all compounds, except the ‘typical’ antipsychotics haloperidol and fluspirilene, showed higher affinity for 5HT2A than for D2 receptors, while in vivo, ORG-5222, risperidone, pipamperone, 9-OH-risperid one, sertindole, olanzapine, zotepine and clozapine maintained a higher potency for occupying 5HT
Journal ArticleDOI
Designed multiple ligands. An emerging drug discovery paradigm.
Richard Morphy,Zoran Rankovic +1 more
Journal ArticleDOI
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
Rudi Pauwels,Koen Andries,Jan Desmyter,Dominique Schols,Michael J. Kukla,Henry J. Breslin,Alfons Raeymaeckers,Jozef H L Van Gelder,Robert Woestenborghs,J. Heykants,K. H. L. Schellekens,Marcel August Constant Janssen,Erik De Clercq,Paul A. J. Janssen +13 more
TL;DR: In this article, a series of tetrahydro-imidazone derivatives of Benzodiazepin-2(1H)-one and -thione (TIBO) derivatives were found to inhibit the replication of HIV-1 and HIV-2.
Journal ArticleDOI
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Jørn Arnt,T Skarsfeldt +1 more
TL;DR: The available evidence indicates that novel APDs and clozapine can be differentiated from haloperidol, particularly in models of EPS and cognitive side effects, however, among the group of novel APD there are many individual differences in models reflecting limbic versus striatal inhibition of dopamine function.
Journal ArticleDOI
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
TL;DR: Risperidone is an effective antipsychotic for the treatment of chronic schizophrenia; doses of 4 and 8 mg seem to be optimal and have a lower incidence of side-effects than haloperidol.